0000000000353390

AUTHOR

Wolfgang Gaebel

showing 24 related works from this author

Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients

2010

To describe the course of positive and negative symptoms during inpatient treatment and examine remission and response rates under routine clinical care conditions.Two hundred and eighty inpatients with schizophrenia (DSM-IV criteria) were assessed with the Positive and Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the symptom-severity component of the consensus criteria (Remission in Schizophrenia Working Group) as a rating of three or less in the relevant PANSS items at discharge, and response as a reduction of at least 20% in the PANSS total score from admission to discharge.The mean duration of in…

AdultMalemedicine.medical_specialtyTime FactorsAntipsychotic treatmentSeverity of Illness IndexYoung Adult03 medical and health sciences0302 clinical medicineNaturalistic observationInternal medicineOutcome Assessment Health CareSeverity of illnessmedicineHumansYoung adultPsychiatryBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleRetrospective cohort studyMiddle Agedmedicine.disease030227 psychiatry3. Good healthDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthSchizophreniaTime courseSchizophreniaRegression AnalysisFemalePsychology030217 neurology & neurosurgeryAntipsychotic AgentsSchizophrenia Research
researchProduct

Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale

2010

Schennach-Wolff R, Obermeier M, Seemuller F, Jager M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller H-J, Riedel M. Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. Objective:  To examine depressive symptoms, their course during treatment, and influence on outcome. Method:  Weekly Calgary Depression Scale for Schizophrenia ratings were performed in 249 inpatients with schizophrenia. Early response was defined as a 20% reduction in the total score of the Positive and Negative Syndrome Scale for Schizophrenia from admission to w…

medicine.medical_specialtyPositive and Negative Syndrome ScaleCase-control studyPoison controlmedicine.disease3. Good health030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineSchizophreniaInternal medicineInjury preventionmedicinemedicine.symptomPsychiatryPsychologySuicidal ideation030217 neurology & neurosurgeryDepression (differential diagnoses)Cohort studyActa Psychiatrica Scandinavica
researchProduct

Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.

2011

Abstract Background To examine the influencing factors and predictors of early improvement in schizophrenia patients. Methods 370 patients suffering from a schizophrenia spectrum disorder were examined within a naturalistic multicenter study. Early improvement was defined as a ≥30% PANSS total score reduction within the first two treatment weeks, response as a ≥50% improvement of the PANSS total score from admission to discharge and remission according to the consensus remission criteria. Baseline and course-related variables such as positive, negative and depressive symptoms, side effects, functioning and subjective well-being were examined regarding their explanatory value for early impro…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMedizinAntipsychotic treatment03 medical and health sciencesYoung Adult0302 clinical medicineRemission criteriaPredictive Value of TestsInternal medicinemedicineHumansPsychiatryAntipsychoticBiological PsychiatryDepressive symptomsRetrospective StudiesPsychiatric Status Rating Scalesbusiness.industryMiddle Agedmedicine.disease030227 psychiatry3. Good healthDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthTreatment OutcomeMulticenter studyROC CurveSchizophreniaSchizophreniaFemalebusiness030217 neurology & neurosurgerySchizophrenia spectrumAntipsychotic AgentsFollow-Up StudiesJournal of psychiatric research
researchProduct

Response trajectories in "real-world" naturalistically treated schizophrenia patients.

2011

Abstract Background To date, research has identified distinct antipsychotic response trajectories yet focussing on data from randomized-controlled trials (RCTs). Therefore, the heterogeneity of response in “real-world” schizophrenia patients is still unknown. Methods Antipsychotic response was evaluated in 399 patients suffering from a schizophrenia spectrum disorder within a naturalistic multicenter study of the Competence Network on Schizophrenia using latent class regression. Baseline and illness-related variables were compared between the different trajectory classes as well as currently proposed outcome definitions (early improvement, response, remission) using univariate tests. In ord…

AdultMaleTime Factorsmedicine.medical_treatmentMedizin03 medical and health sciencesYoung Adult0302 clinical medicinemedicineHumansYoung adultAntipsychoticBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesUnivariateRetrospective cohort studyRegression analysisMiddle AgedResponse to treatment030227 psychiatryDiagnostic and Statistical Manual of Mental DisordersHospitalizationPsychiatry and Mental healthTreatment OutcomeMulticenter studySchizophreniaRegression AnalysisFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgeryClinical psychologySchizophrenia spectrumAntipsychotic AgentsFollow-Up StudiesSchizophrenia research
researchProduct

Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders : Valid predictors of symptomatic response and remiss…

2010

To examine quality of life and subjective well-being as predictors of symptomatic treatment outcome.Biweekly PANSS ratings were performed in 285 inpatients with schizophrenia spectrum disorders within a multicenter trial by the German Research Network on Schizophrenia. Quality of life and subjective well-being were assessed using the Medical Outcomes Study-Short Form 36-Item Health Survey (SF-36), the Subjective Well-being Under Neuroleptic Treatment Scale (SWN-K) and the Adjective Mood Scale (AMS). Response was defined as an initial 20% PANSS total score reduction and remission according to the consensus criteria. Correlation analysis, logistic regression and CART-analysis were performed.I…

AdultMalemedicine.medical_specialtyMedizinLogistic regressionMood scale03 medical and health sciencesYoung Adult0302 clinical medicineQuality of lifeMulticenter trialInternal medicinemedicineHumansSubjective well-beingBiological PsychiatryPsychiatric Status Rating ScalesMiddle Agedmedicine.diseasePrognosisAntidepressive Agents3. Good health030227 psychiatryHospitalizationPsychiatry and Mental healthTranquilizing AgentsPsychotic DisordersSchizophreniaCorrelation analysisQuality of LifeSchizophreniaDrug Therapy CombinationFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgerySchizophrenia spectrumClinical psychologyAntipsychotic Agents
researchProduct

Insight in schizophrenia–course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder

2012

AbstractBackgroundTo analyse insight of illness during the course of inpatient treatment, and to identify influencing factors and predictors of insight.MethodsInsight into illness was examined in 399 patients using the item G12 of the Positive and Negative Syndrome Scale (“lack of insight and judgement”). Ratings of the PANSS, HAMD, UKU, GAF, SOFAS, SWN-K and Kemp's compliance scale were performed and examined regarding their potential association with insight. The item G12 was kept as an ordinal variable to compare insight between subgroups of patients.ResultsAlmost 70% of patients had deficits in their insight into illness at admission. A significant improvement of impairments of insight …

AdultMaleOrdinal datamedicine.medical_specialtyMedizin03 medical and health sciences0302 clinical medicineTreatment targetsPredictive Value of TestsHamdmedicineHumansPsychiatryPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleAwarenessmedicine.disease030227 psychiatryPsychiatry and Mental healthInsight into illnessSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgeryClinical psychologySchizophrenia spectrumEuropean Psychiatry
researchProduct

Outcome of suicidal patients with schizophrenia: results from a naturalistic study.

2010

Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller H-J, Riedel M. Outcome of suicidal patients with schizophrenia: results from a naturalistic study. Objective:  Purpose was to assess suicidality before and at the time of admission in patients with schizophrenia and compare outcome differences. Method:  Biweekly PANSS (Positive and Negative Syndrome Scale), HAMD (Hamilton Depression Rating Scale) and UKU (Udvalg for Klinske Undersogelser Side Effect Rating Scale) ratings were evaluated in 339 in-patients with schizophrenic spectrum disorder…

AdultMalemedicine.medical_specialtyPsychosisMedizinPoison controlSuicide AttemptedComorbidityAkathisiaCohort StudiesHospitals University03 medical and health sciencesYoung Adult0302 clinical medicineRating scaleRisk FactorsGermanyHamdmedicineHumansPsychiatryPsychiatric Status Rating ScalesDepressive Disorder MajorPositive and Negative Syndrome ScaleIncidenceMiddle Agedmedicine.diseaseComorbidityHealth Surveys3. Good health030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesTreatment OutcomeSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychology030217 neurology & neurosurgeryAkathisia Drug-InducedAntipsychotic AgentsActa psychiatrica Scandinavica
researchProduct

What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder?

2014

AbstractBackground:Aim was to examine depressive symptoms in acutely ill schizophrenia patients on a single symptom basis and to evaluate their relationship with positive, negative and general psychopathological symptoms.Methods:Two hundred and seventy-eight patients suffering from a schizophrenia spectrum disorder were analysed within a naturalistic study by the German Research Network on Schizophrenia. Using the Calgary Depression Scale for Schizophrenia (CDSS) depressive symptoms were examined and the Positive and Negative Syndrome Scale (PANSS) was applied to assess positive, negative and general symptoms. Correlation and factor analyses were calculated to detect the underlying structur…

AdultMalemedicine.medical_specialtyDepression scaleMedizinSeverity of Illness Index03 medical and health sciences0302 clinical medicineGermanyPrevalencemedicineHumans030212 general & internal medicinePsychiatryDepression (differential diagnoses)Depressive symptomsPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleDepressionGeneral symptomsMiddle Agedmedicine.disease030227 psychiatry3. Good healthHospitalizationAffectPsychiatry and Mental healthResearch DesignSchizophreniaAcute DiseaseGuiltSchizophreniaFemaleSchizophrenic PsychologyFactor Analysis StatisticalPsychologyPsychopathologyClinical psychologySchizophrenia spectrumEuropean Psychiatry
researchProduct

Attitude towards adherence in patients with schizophrenia at discharge

2009

Abstract Background Purpose of the present study was to assess the attitude towards adherence at discharge and to verify its predictability using anamnestic and sociodemographic variables, factors influencing clinical treatment as well as the medical treatment applied. Methods Attitude towards adherence was evaluated in 369 inpatients with schizophrenic spectrum disorders within a naturalistic multicenter trial using the Compliance Rating Scale (CRS) by Kemp. Biweekly ratings of the PANSS, UKU and the Subjective Well-being under Neuroleptic Treatment Scale (SWN-K) were applied. Logistic regression and CART analyses were used to determine significant predictor variables for the attitude towa…

AdultMalemedicine.medical_specialtyPsychosisTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticLogistic regressionStatistics NonparametricMedication Adherence03 medical and health sciences0302 clinical medicineRating scaleSurveys and QuestionnairesMulticenter trialmedicinePsychoeducationHumansPsychiatryBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesMiddle Agedmedicine.diseasePatient Discharge3. Good health030227 psychiatryPsychiatry and Mental healthSchizophreniaSchizophreniaFemaleSchizophrenic PsychologyPsychologyAttitude to Health030217 neurology & neurosurgeryFollow-Up StudiesClinical psychologyPsychopathologyJournal of Psychiatric Research
researchProduct

Genetic contribution to alcohol dependence: Investigation of a heterogeneous german sample of individuals with alcohol dependence, chronic alcoholic …

2017

The present study investigated the genetic contribution to alcohol dependence (AD) using genome-wide association data from three German samples. These comprised patients with: (i) AD; (ii) chronic alcoholic pancreatitis (ACP); and (iii) alcohol-related liver cirrhosis (ALC). Single marker, gene-based, and pathway analyses were conducted. A significant association was detected for the ADH1B locus in a gene-based approach (puncorrected = 1.2 × 10-6; pcorrected = 0.020). This was driven by the AD subsample. No association with ADH1B was found in the combined ACP + ALC sample. On first inspection, this seems surprising, since ADH1B is a robustly replicated risk gene for AD and may therefore be …

0301 basic medicinemedicine.medical_specialtyCirrhosislcsh:QH426-470alcohol dependenceMedizinGenome-wide association studyLocus (genetics)610 Medicine & healthGastroenterologyArticle03 medical and health sciencesLiver diseaseInternal medicineGeneticsMedicine610 Medicine &amp; healthAllele frequencyGenetics (clinical)genome-wide association studybusiness.industryAlcohol dependencealcohol dehydrogenaseADH1Bchronic alcoholic pancreatitisalcohol dependence; chronic alcoholic pancreatitis; alcoholic liver cirrhosis; genome-wide association study; alcohol dehydrogenase; <i>ADH1B</i>; <i>ADH1C</i>medicine.diseaseADH1CADH1Blcsh:Genetics030104 developmental biologyPancreatitisalcoholic liver cirrhosisbusiness
researchProduct

Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change met…

2015

Significant changes of schizophrenia patients during inpatient treatment were evalutaed and compared to established outcome criteria. The concept of reliable and clinically significant change methods was applied to three hundred and ninety-six patients suffering from a schizophrenia spectrum disorder. First, information on whether or not the change of the patient's condition is sufficient in order to declare that it is beyond a measurement error or random effect (= reliable change) was evaluated and in a second step it was observed if the reliable change was clinically meaningful (= clinically significant change). Different Positive and Negative Syndrome Scale for Schizophrenia (PANSS) thre…

medicine.medical_specialtyPositive and Negative Syndrome ScaleRetrospective cohort studyOutcome assessmentmedicine.diseaseOutcome (game theory)3. Good health030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicineSchizophreniaInternal medicinemedicinesense organsAnalysis of varianceYoung adultskin and connective tissue diseasesPsychology030217 neurology & neurosurgeryClinical psychologySchizophrenia spectrumInternational Journal of Methods in Psychiatric Research
researchProduct

Prediction of symptom remission in schizophrenia during inpatient treatment

2007

Standardized consensus criteria for remission in schizophrenia were recently proposed. The present study applied the symptom-severity component of these criteria to a sample of inpatients in order to determine the rates of remission during inpatient treatment and to explore predictors of remission.A total of 288 inpatients from a multi-centre follow-up programme who fulfilled ICD-10 criteria for schizophrenia were included in the present analyses. PANSS ratings at admission and at discharge from hospitalization were used to examine remission status. Clinical and sociodemographic variables at admission were tested for their ability to predict remission at discharge.In total, 55% of the sampl…

AdultMalemedicine.medical_specialtyTreatment outcomeConsensus criteriaLogistic regressionYoung Adult03 medical and health sciences0302 clinical medicineInternational Classification of DiseasesGermanyInternal medicineInterview PsychologicalmedicineHumansYoung adultPsychiatryBiological PsychiatryPsychiatric Status Rating ScalesModels StatisticalFollow up studiesMiddle AgedPrognosismedicine.disease030227 psychiatryHospitalizationPsychiatry and Mental healthTreatment OutcomeROC CurveMulticenter studySchizophreniaPsychiatric status rating scalesSchizophreniaFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgeryFollow-Up StudiesThe World Journal of Biological Psychiatry
researchProduct

Genome-wide Association Study of Alcohol Dependence

2009

Context Alcohol dependence is a serious and common public health problem. It is well established that genetic factors play a major role in the development of this disorder. Identification of genes that contribute to alcohol dependence will improve our understanding of the mechanisms that underlie this disorder. Objective To identify susceptibility genes for alcohol dependence through a genome-wide association study (GWAS) and a follow-up study in a population of German male inpatients with an early age at onset. Design The GWAS tested 524 396 single-nucleotide polymorphisms (SNPs). All SNPs with P −4 were subjected to the follow-up study. In addition, nominally significant SNPs from genes t…

AdultGenetic MarkersMaleGenotypeGenetic LinkagePopulationContext (language use)Single-nucleotide polymorphismGenome-wide association studyBiologyPolymorphism Single NucleotideGenetic determinismArticleAlcohol Withdrawal DeliriumYoung AdultArts and Humanities (miscellaneous)Genetic linkageAnimalsHumansAlleleAge of OnseteducationAllelesGeneticseducation.field_of_studyGene Expression ProfilingAlcohol dependenceAlcohol DehydrogenasePutamenRats Inbred StrainsAmygdalaCadherinsRatsHospitalizationPsychiatry and Mental healthAlcoholismPhenotypeGene Expression RegulationCase-Control StudiesChromosomes Human Pair 2Caudate NucleusLod ScoreFollow-Up StudiesGenome-Wide Association Study
researchProduct

XRCC5 as a Risk Gene for Alcohol Dependence : Evidence from a Genome-Wide Gene-Set-Based Analysis and Follow-up Studies in Drosophila and Humans

2015

Genetic factors play as large a role as environmental factors in the etiology of alcohol dependence. Although genome-wide association studies (GWAS) enable systematic searches for loci not hitherto implicated in the etiology of alcohol dependence, many true findings may be missed due to correction for multiple testing. The aim of the present study was to circumvent this limitation by searching for biological system-level differences, and then following up these findings in humans and animals. Gene-set based analysis of GWAS data from 1333 cases and 2168 controls identified 19 significantly associated gene-sets of which five could be replicated in an independent sample. Clustered in these ge…

MaleRiskAdolescentMedizinGenome-wide association studyBiologyPolymorphism Single NucleotideWhite PeopleAnimals Genetically ModifiedRNA interferenceGermanyGenetic variationAnimalsHumansGene silencingGenetic Predisposition to DiseaseKu AutoantigenGeneGenetic associationPharmacologyGeneticsEthanolAlcohol dependenceDNA HelicasesCentral Nervous System DepressantsPhenotypeAlcoholismPsychiatry and Mental healthDrosophila melanogasterFemaleOriginal ArticleFollow-Up StudiesGenome-Wide Association Study
researchProduct

Neural correlates of working memory dysfunction in first-episode schizophrenia patients: an fMRI multi-center study.

2005

Working memory dysfunction is a prominent impairment in patients with schizophrenia. Our aim was to determine cerebral dysfunctions by means of functional magnetic resonance imaging (fMRI) in a large sample of first-episode schizophrenia patients during a working memory task. 75 first-episode schizophrenia patients and 81 control subjects, recruited within a multi-center study, performed 2- and 0-back tasks while brain activation was measured with fMRI. In order to guarantee comparability between data quality from different scanners, we developed and adopted a standardized, fully automated quality assurance of scanner hard- and software as well as a measure for in vivo data quality. After t…

AdultMaleVentrolateral prefrontal cortexAdolescentPrecuneusPrefrontal CortexSerial LearningTemporal lobeThalamusReference ValuesmedicineImage Processing Computer-AssistedReaction TimeHumansAttentionPrefrontal cortexBiological PsychiatryTemporal cortexn-backBrain Mappingmedicine.diagnostic_testWorking memoryMiddle AgedMagnetic Resonance ImagingTemporal LobePsychiatry and Mental healthmedicine.anatomical_structureMemory Short-TermPattern Recognition VisualSchizophreniaFemaleNerve NetPsychologyFunctional magnetic resonance imagingNeuroscienceSchizophrenia research
researchProduct

Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study

2009

AbstractObjectiveTo examine the predictive validity of early improvement in a naturalistic sample of inpatients and to identify the criterion that best defines early improvement.MethodsTwo hundred and forty-seven inpatients who fulfilled ICD-10 criteria for schizophrenia were assessed with the Positive And Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the recently proposed consensus criteria, response as a reduction of at least 40% in the PANNS total score from admission to discharge.ResultsReceiver operating characteristic (ROC) analyses showed that early improvement (reduction of the PANSS total sco…

AdultMalePredictive validitymedicine.medical_specialtyDrug trialAdolescentmedicine.medical_treatmentConsensus criteriaSensitivity and SpecificitySeverity of Illness Index03 medical and health sciences0302 clinical medicineNaturalistic observationInternational Classification of DiseasesInternal medicinemedicineHumans030212 general & internal medicinePsychiatryAntipsychoticAgedPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleReceiver operating characteristicPatient SelectionMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthTranquilizing AgentsTreatment OutcomeROC CurveSchizophreniaArea Under CurveSchizophreniaFemalePsychologyAntipsychotic AgentsFollow-Up StudiesEuropean Psychiatry
researchProduct

Repetitive Transcranial Magnetic Stimulation (rTMS) Improves Facial Affect Recognition in Schizophrenia

2014

Abstract Objective Facial affect recognition, a basic building block of social cognition, is often impaired in schizophrenia. Poor facial affect recognition is closely related to poor functional outcome; however, neither social cognitive impairments nor functional outcome are sufficiently improved by antipsychotic drug treatment alone. Adjunctive repetitive transcranial magnetic stimulation (rTMS) has been shown to enhance cognitive functioning in both healthy individuals and in people with neuropsychiatric disorders and to ameliorate clinical symptoms in psychiatric disorders, but its effects on social cognitive impairments in schizophrenia have not yet been studied. Therefore, we evaluate…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentBiophysicsPrefrontal CortexStimulationAudiologylcsh:RC321-571Young AdultCognitionDouble-Blind MethodSocial cognitionRepetitive transcranial magnetic stimulation (rTMS)medicineHumansIn patientCognitive skillPsychiatrylcsh:Neurosciences. Biological psychiatry. NeuropsychiatryFacial affectGeneral NeuroscienceMiddle Agedmedicine.diseaseTranscranial Magnetic StimulationFacial affect recognitionTranscranial magnetic stimulationFacial ExpressionAffectSchizophreniaSchizophreniaChronic schizophreniaFemaleSchizophrenic PsychologyNeurology (clinical)PsychologyCognition DisordersBrain Stimulation
researchProduct

Genome-wide significant association between alcohol dependence and a variant in the ADH gene cluster

2011

Alcohol dependence (AD) is an important contributory factor to the global burden of disease. The etiology of AD involves both environmental and genetic factors, and the disorder has a heritability of around 50%. The aim of the present study was to identify susceptibility genes for AD by performing a genome-wide association study (GWAS). The sample comprised 1333 male in-patients with severe AD according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, and 2168 controls. These included 487 patients and 1358 controls from a previous GWAS study by our group. All individuals were of German descent. Single-marker tests and a polygenic score-based analysis to assess the …

PharmacologyGeneticsPsychiatry and Mental healthLinkage disequilibriumPolymorphism (computer science)Gene clusterMedicine (miscellaneous)SNPADH1BSingle-nucleotide polymorphismGenome-wide association studyBiologyHeritabilityAddiction Biology
researchProduct

Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.

2009

Abstract Background: To assess criteria and to identify predictive factors for functional outcome. The criteria should cover all domains proposed by the Remission in Schizophrenia Working Group. Method: PANSS ratings were used to evaluate the symptomatic treatment outcome of 262 inpatients with schizophrenia spectrum disorders within a naturalistic multicenter trial. Functional remission was defined as a GAF score > 61 (Global Assessment of Functioning Scale), SOFAS score > 61 (Social and Occupational Functioning Scale) and a SF-36 mental health subscore > 40 (Medical Outcomes Study—Short Form Health Survey). Multivariate logistic regression and CART analyses were used to determine valid cl…

AdultMalemedicine.medical_specialtySF-36Global Assessment of FunctioningNeuropsychological TestsLogistic regressionSeverity of Illness IndexDevelopmental psychology03 medical and health sciencesYoung Adult0302 clinical medicinePredictive Value of TestsRecurrenceInternal medicineMulticenter trialSeverity of illnessOutcome Assessment Health CaremedicineHumansBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesMiddle Agedmedicine.disease030227 psychiatry3. Good healthPsychiatry and Mental healthPsychotic DisordersROC CurveSchizophreniaPredictive value of testsSchizophreniaRegression AnalysisFemaleSchizophrenic PsychologyPsychologyPsychosocial030217 neurology & neurosurgeryFollow-Up StudiesSchizophrenia research
researchProduct

Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders.

2009

AbstractBackgroundPurpose of this study was to assess subjective well-being in schizophrenia inpatients and to find variables predictive for response and remission of subjective well-being.MethodThe subjective well-being under neuroleptic treatment scale (SWN-K) was used in 232 schizophrenia patients within a naturalistic multicenter trial. Early response was defined as a SWN-K total score improvement of 20% and by at least 10 points within the first 2 treatment weeks, response as an improvement in SWN-K total score of at least 20% and by at least 10 points from admission to discharge and remission in subjective well-being as a total score of more or equal to 80 points at discharge. Logisti…

AdultMalemedicine.medical_specialtyPsychosisMedizinPersonal SatisfactionLogistic regressionSeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineMulticenter trialmedicineHumansIn patient030212 general & internal medicineSubjective well-beingPsychiatryPsychiatric Status Rating ScalesDepressionMiddle Agedmedicine.disease3. Good health030227 psychiatryPsychiatry and Mental healthTreatment OutcomeSchizophreniaPsychological well-beingQuality of LifeSchizophreniaFemaleSchizophrenic PsychologyPsychologyEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response

2008

The aim of the present study was to examine the relevance of depressive symptoms during an acute schizophrenic episode for the prediction of treatment response. Two hundred inpatients who fulfilled DSM-IV criteria for schizophrenia or schizophreniform disorders were assessed at hospital admission and after 6 weeks of inpatient treatment using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Rating Scale for Depression (HAM-D). Depressive symptoms showed positive correlations with both positive and negative symptoms at admission and after 6 weeks, and decreased during 6 weeks of treatment. Pronounced depressive symptoms (HAM-D score> or =16) were found in 28% of the sample a…

AdultMalemedicine.medical_specialtyPsychosis610 Medicine & healthComorbidity10056 Clinic for Clinical and Social Psychiatry Zurich West (former)law.invention2738 Psychiatry and Mental Health03 medical and health sciencesPatient Admission0302 clinical medicineRandomized controlled triallawInternal medicinemental disordersmedicineHumansSchizophreniform disorderPsychiatryBiological PsychiatryDepression (differential diagnoses)ProbabilityPsychiatric Status Rating ScalesDepressive DisorderDepressive Disorder MajorPsychotropic DrugsPositive and Negative Syndrome ScaleHamilton Rating Scale for Depressionmedicine.diseaseComorbidity030227 psychiatryDiagnostic and Statistical Manual of Mental DisordersHospitalizationPsychiatry and Mental healthTreatment OutcomePsychotic DisordersSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychology2803 Biological Psychiatry030217 neurology & neurosurgeryAntipsychotic AgentsFollow-Up Studies
researchProduct

Shared genetic etiology between alcohol dependence and major depressive disorder

2018

Supplemental Digital Content is available in the text.

Male0301 basic medicineOncologyAlcoholism/geneticsMultifactorial Inheritancealcohol dependenceMedizinGenome-wide association study0302 clinical medicineRisk FactorsGermanyMedicineGenetics (clinical)Brief ReportRegression analysisAlcoholismPsychiatry and Mental healthpolygenic risk scoresMeta-analysisComputingMethodologies_DOCUMENTANDTEXTPROCESSINGRegression AnalysisMajor depressive disorderdisease comorbidityDepressive Disorder Major/geneticsmedicine.medical_specialtyBFPolymorphism Single Nucleotide03 medical and health sciencespsychiatric genomics consortiumInternal medicineGeneticsHumansGenetic Predisposition to Diseaseddc:610Biological PsychiatryDepressive Disorder Majormajor depressive disorderbusiness.industryAlcohol dependenceCase-control studymedicine.diseaseComorbidity030104 developmental biologySample size determinationCase-Control Studiesgenome-wide association studiesRC0321business030217 neurology & neurosurgeryGenome-Wide Association Study
researchProduct

Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How?

2017

Abstract The aim of this study was to evaluate antidepressant add-on treatment within the acute treatment of schizophrenia spectrum disorder patients. Antidepressant add-on was evaluated in 365 patients within a naturalistic multicenter study. Patients with/without antidepressant add-on were compared regarding clinical and treatment-related variables, response and remission, and remission of depressive and negative symptoms. The efficacy of antidepressant add-on treatment was furthermore analyzed applying marginal structure models. Twenty-three percent of the patients received antidepressant add-on for a mean duration of 50.28 (33.42) days. Patients with the diagnosis of a schizoaffective d…

AdultMalemedicine.medical_specialtyAdolescentMedizinSchizoaffective disorderDrug synergismYoung Adult03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)Young adultPsychiatryDepressive symptomsAgedDepressionDrug SynergismGeneral MedicineMiddle Agedmedicine.diseaseAntidepressive Agents3. Good health030227 psychiatryClinical trialPsychiatry and Mental healthTreatment OutcomeMulticenter studySchizophreniaAntidepressantFemalePsychology030217 neurology & neurosurgeryAntipsychotic AgentsSchizophrenia spectrumPharmacopsychiatry
researchProduct

Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remissio…

2019

Despite being recommended for use in clinical trials, the consensus remission criteria were found to leave patients with persisting symptoms, relevant areas of functional impairment and a decreased sense of wellbeing. Therefore, to evaluate the appropriateness of the schizophrenia consensus criteria, a definition of remission based on the Clinical Global Impression Scale (CGI) was developed and remitter subgroups were compared.239 patients with a schizophrenia spectrum disorder were evaluated regarding their remission status after inpatient treatment. Remission in schizophrenia was defined according to the symptom-severity component of the consensus criteria by Andreasen et al. and a CGI ba…

AdultMalePediatricsmedicine.medical_specialtyConsensusMedizinConsensus criteriaSeverity of Illness IndexAsymptomaticYoung Adult03 medical and health sciences0302 clinical medicineRemission criteriaOutcome Assessment Health Caremental disordersmedicineHumansBiological PsychiatryDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryRemission InductionMiddle Agedmedicine.disease030227 psychiatry3. Good healthClinical trialPsychiatry and Mental healthSchizophreniaSchizophreniaClinical Global ImpressionFemalemedicine.symptombusiness030217 neurology & neurosurgeryFollow-Up StudiesSchizophrenia spectrum
researchProduct